Drug development for severe asthma: What are the metrics?

Pharmacology and Therapeutics

Volumn 135, Issue 2, 2012, Pages 176-181

  Robinson, Cynthia B ^a   Leonard, Joanne ^a   Panettieri Jr , Reynold A ^b  

^a Epigenesis Pharmaceuticals   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Airway remodeling; Drug discovery; Fixed airway obstruction; Irreversible asthma

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL; OMALIZUMAB; PREDNISONE; STEROID;

AIRWAY OBSTRUCTION; AIRWAY REMODELING; ASTHMA; BRONCHODILATATION; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MEDLINE; MUSCLE FUNCTION; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REVIEW; SPIROMETRY;

ANTI-ASTHMATIC AGENTS; ASTHMA; DRUG DISCOVERY; HUMANS; RESPIRATORY FUNCTION TESTS;

EID: 84862680475     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2012.05.005     Document Type: Review

References (34)

1. Arbes, S. J., Jr., Gergen, P. J., Vaughn, B., & Zeldin, D. C. (2007). Asthma cases attributable to atopy: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 120, 1139-1145.
2. National Asthma Education and Prevention Program, N.-N. (2007). Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. In (Vol. NIH Publication No. 07-4051, pp. http://www.nhlbi.nih.gov/guidelines/asthma/ index.html): U.S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute.
3. Asthma Insight and Management (2009). http://www.takingaimatasthma.com/ pdf/executive-summary.pdf
4. Bateman, E. D., Clark, T. J., Frith, L., Bousquet, J., Busse, W. W., & Pedersen, S. E. (2007). Rate of response of individual asthma control measures varies and may over-estimate asthma control: an analysis of the goal study. J Asthma 44, 667-673.
5. Boulet, L. P., Phillips, R., O'Byrne, P., & Becker, A. (2002). Evaluation of asthma control by physicians and patients: comparison with current guidelines. Can Respir J 9, 417-423.
6. Brightling, C., Berry, M., & Amrani, Y. (2008). Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol 121, 5-10.
7. Castro, M., Rubin, A. S., Laviolette, M., Fiterman, J., De Andrade Lima, M., Shah, P. L., et al. (2010). Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 181, 116-124.
8. Chapman, K. R., Boulet, L. P., Rea, R. M., & Franssen, E. (2008). Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J 31, 320-325.
9. Djukanovic, R., Wilson, S. J., Kraft, M., Jarjour, N. N., Steel, M., Chung, K. F., et al. (2004). Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170, 583-593.
10. Erin, E. M., Leaker, B. R., Nicholson, G. C., Tan, A. J., Green, L. M., Neighbour, H., et al. (2006). The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 174, 753-762.
11. Fuhlbrigge, A., Reed, M. L., Stempel, D. A., Ortega, H. O., Fanning, K., & Stanford, R. H. (2009). The status of asthma control in the U.S. adult population. Allergy Asthma Proc 30, 529-533.
12. GINA (). The Global Initiative for Asthma. http://www.ginasthma.org/
13. Goleva, E., Hauk, P. J., Boguniewicz, J., Martin, R. J., & Leung, D. Y. (2007). Airway remodeling and lack of bronchodilator response in steroid-resistant asthma. J Allergy Clin Immunol 120, 1065-1072.
14. Holgate, S. T. (2011). Pathophysiology of asthma: what has our current understanding taught us about new therapeutic approaches? J Allergy Clin Immunol 128, 495-505.
15. Holgate, S. T., Holloway, J., Wilson, S., Howarth, P. H., Haitchi, H. M., Babu, S., et al. (2006). Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities. J Allergy Clin Immunol 117, 496-506.
16. Howarth, P. H., Babu, K. S., Arshad, H. S., Lau, L., Buckley, M., McConnell, W., et al. (2005). Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 60, 1012-1018.
17. Hudon, C., Turcotte, H., Laviolette, M., Carrier, G., & Boulet, L. P. (1997). Characteristics of bronchial asthma with incomplete reversibility of airflow obstruction. Ann Allergy Asthma Immunol 78, 195-202.
18. Jarjour, N. N., Erzurum, S. C., Bleecker, E. R., Calhoun, W. J., Castro, M., Comhair, S. A., et al. (2012). Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med 185, 356-362.
19. Juniper, E. F., Bousquet, J., Abetz, L., & Bateman, E. D. (2006). Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med 100, 616-621.
20. Lotvall, J., Akdis, C. A., Bacharier, L. B., Bjermer, L., Casale, T. B., Custovic, A., et al. (2011). Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 127, 355-360.
21. Macedo, P., Hew, M., Torrego, A., Jouneau, S., Oates, T., Durham, A., et al. (2009). Inflammatory biomarkers in airways of patients with severe asthma compared with non-severe asthma. Clin Exp Allergy 39, 1668-1676.
22. Marcus, P., Arnold, R. J., Ekins, S., Sacco, P., Massanari, M., Stanley Young, S., et al. (2008). A retrospective randomized study of asthma control in the US: results of the CHARIOT study. Curr Med Res Opin 24, 3443-3452.
23. Meltzer, E. O. (2003). The role of the immune system in the pathogenesis of asthma and an overview of the diagnosis, classification, and current approach to treating the disease. J Manag Care Pharm 9, 8-13.
24. Miller, M. K., Lee, J. H., Miller, D. P., & Wenzel, S. E. (2007). Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med 101, 481-489.
25. Moore, W. C., Bleecker, E. R., Curran-Everett, D., Erzurum, S. C., Ameredes, B. T., Bacharier, L., et al. (2007). Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 119, 405-413.
26. Moore, W. C., Meyers, D. A., Wenzel, S. E., Teague, W. G., Li, H., Li, X., et al. (2010). Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 181, 315-323.
27. Nathan, R. A., Sorkness, C. A., Kosinski, M., Schatz, M., Li, J. T., Marcus, P., et al. (2004). Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 113, 59-65.
28. Omalizumab Summary Basis of Approval. http://www.fda.gov/
29. Prieto, L., Gutierrez, V., Colas, C., Tabar, A., Perez-Frances, C., Bruno, L., et al. (2006). Effect of omalizumab on adenosine 5?-monophosphate responsiveness in subjects with allergic asthma. Int Arch Allergy Immunol 139, 122-131.
30. Rasmussen, F., Taylor, D. R., Flannery, E. M., Cowan, J. O., Greene, J. M., Herbison, G. P., et al. (2002). Risk factors for airway remodeling in asthma manifested by a low postbronchodilator FEV1/vital capacity ratio: A longitudinal population study from childhood to adulthood. Am J Respir Crit Care Med 165, 1480-1488.
31. Reddel, H. K., Taylor, D. R., Bateman, E. D., Boulet, L. P., Boushey, H. A., Busse, W. W., et al. (2009). An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 180, 59-99.
32. Stanford, R. H., Gilsenan, A. W., Ziemiecki, R., Zhou, X., Lincourt, W. R., & Ortega, H. (2010). Predictors of uncontrolled asthma in adult and pediatric patients: Analysis of the Asthma Control Characteristics and Prevalence Survey Studies (ACCESS). J Asthma 47, 257-262.
33. Ulrik, C. S., & Backer, V. (1999). Nonreversible airflow obstruction in life-long non-smokers with moderate to severe asthma. Eur Respir J 14, 892-896.
34. Wenzel, S. E., Barnes, P. J., Bleecker, E. R., Bousquet, J., Busse, W., Dahlen, S. E., et al. (2009). A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 179, 549-558.